Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;58(7):819-830.
doi: 10.1007/s00592-020-01656-9. Epub 2021 Feb 2.

Novel biomarkers of diabetic kidney disease: current status and potential clinical application

Federica Barutta  1 , Stefania Bellini  2 , Silvia Canepa  2 , Marilena Durazzo  2 , Gabriella Gruden  2
Affiliations
Free article
Review

Novel biomarkers of diabetic kidney disease: current status and potential clinical application

Federica Barutta et al. Acta Diabetol. 2021 Jul.
Free article

Erratum in

Abstract

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD). Although both albuminuria and glomerular filtration rate (GFR) are well-established diagnostic/prognostic biomarkers of DKD, they have important limitations. There is, thus, increasing quest to find novel biomarkers to identify the disease in an early stage and to improve risk stratification. In this review, we will outline the major pitfalls of currently available markers, describe promising novel biomarkers, and discuss their potential clinical relevance. In particular, we will focus on the importance of recent advancements in multi-omic technologies in the discovery of new DKD biomarkers. In addition, we will provide an update on new emerging approaches to explore renal function and structure, using functional tests and imaging.

Keywords: Albuminuria; Biomarkers; Diabetic kidney disease; Glomerular filtration rate; Omics.

PubMed Disclaimer

References

    1. Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12:2032–2045. https://doi.org/10.2215/CJN.11491116 - DOI - PubMed - PMC
    1. Penno G, Solini A, Bonora E et al (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. https://doi.org/10.1097/HJH.0b013e3283495cd6 - DOI
    1. Gonzalez Suarez ML, Thomas DB, Barisoni L, Fornoni A (2013) Diabetic nephropathy: is it time yet for routine kidney biopsy? World J Diabet 4:245–255. https://doi.org/10.4239/wjd.v4.i6.245 - DOI
    1. Caramori ML (2017) Should all patients with diabetes have a kidney biopsy? Nephrol Dial Transplant 32:3–5. https://doi.org/10.1093/ndt/gfw389 - DOI
    1. Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. CJASN 12:2032–2045. https://doi.org/10.2215/CJN.11491116 - DOI - PubMed - PMC

MeSH terms